Cargando…
Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
PURPOSE: The aim of this retrospective review was to compare the efficacy and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen versus the carboplatin and nab-paclitaxel regimen as front-line management for treatment-naïve, metastatic nonsquamous programmed death-ligand 1 (PD-L1...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508031/ https://www.ncbi.nlm.nih.gov/pubmed/34973080 http://dx.doi.org/10.1007/s00432-021-03873-3 |
_version_ | 1784796931207200768 |
---|---|
author | Xu, Bo Cheng, Huihui Li, Kunhong Lv, Yukai Zeng, Xianshang Liu, Tao Yu, Weiguang Guo, Wenbo |
author_facet | Xu, Bo Cheng, Huihui Li, Kunhong Lv, Yukai Zeng, Xianshang Liu, Tao Yu, Weiguang Guo, Wenbo |
author_sort | Xu, Bo |
collection | PubMed |
description | PURPOSE: The aim of this retrospective review was to compare the efficacy and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen versus the carboplatin and nab-paclitaxel regimen as front-line management for treatment-naïve, metastatic nonsquamous programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in a selected population. METHODS: Consecutive patients with untreated, metastatic nonsquamous PD-L1-positive NSCLC who initially received the atezolizumab plus carboplatin and nab-paclitaxel (ACN) regimen or carboplatin and nab-paclitaxel (CN) regimen were retrospectively identified in two medical institutions from 2017 to 2020. The co-primary end points were overall survival (OS) and progression-free survival (PFS); secondary end point was the rate of key adverse events (AEs). RESULTS: In sum, 171 patients were retrospectively analysed, 47 of whom were excluded according to the criteria used in this study, leaving 124 patients (ACN: n = 60, median age 64 years [range 46–75]; CN: n = 64, 63 years [47–72]). The median duration of follow-up was 27 months [range 1–37]. At the final follow-up, the median OS was 19.9 months (95% confidence interval [CI], 16.3–22.5) in the ACN group vs. 14.8 months (95% CI 12.5–17.2) in the CN group (hazard ratio [HR] 0.51, 95% CI 0.33–0.77; p = 0.001). A marked distinction in the median PFS was seen (8.5 months [95% CI 6.7–9.4] in the ACN group vs. in the CN group [5.1 months [95% CI 3.6–6.8; HR 0.60; 95% CI 0.38–0.95; p = 0.005]). The rates of the key AEs (neutropenia and anaemia) were greater in the ACN group than in the CN group (all p < 0.05), but these AEs were manageable. CONCLUSION: Among selected populations of individuals with treatment-naïve, metastatic nonsquamous PD-L1-positive NSCLC, atezolizumab combined with carboplatin and nab-paclitaxel chemotherapy might have encouraging anticancer activity, with a tolerable safety profile. |
format | Online Article Text |
id | pubmed-9508031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-95080312022-09-25 Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study Xu, Bo Cheng, Huihui Li, Kunhong Lv, Yukai Zeng, Xianshang Liu, Tao Yu, Weiguang Guo, Wenbo J Cancer Res Clin Oncol Original Article – Clinical Oncology PURPOSE: The aim of this retrospective review was to compare the efficacy and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen versus the carboplatin and nab-paclitaxel regimen as front-line management for treatment-naïve, metastatic nonsquamous programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in a selected population. METHODS: Consecutive patients with untreated, metastatic nonsquamous PD-L1-positive NSCLC who initially received the atezolizumab plus carboplatin and nab-paclitaxel (ACN) regimen or carboplatin and nab-paclitaxel (CN) regimen were retrospectively identified in two medical institutions from 2017 to 2020. The co-primary end points were overall survival (OS) and progression-free survival (PFS); secondary end point was the rate of key adverse events (AEs). RESULTS: In sum, 171 patients were retrospectively analysed, 47 of whom were excluded according to the criteria used in this study, leaving 124 patients (ACN: n = 60, median age 64 years [range 46–75]; CN: n = 64, 63 years [47–72]). The median duration of follow-up was 27 months [range 1–37]. At the final follow-up, the median OS was 19.9 months (95% confidence interval [CI], 16.3–22.5) in the ACN group vs. 14.8 months (95% CI 12.5–17.2) in the CN group (hazard ratio [HR] 0.51, 95% CI 0.33–0.77; p = 0.001). A marked distinction in the median PFS was seen (8.5 months [95% CI 6.7–9.4] in the ACN group vs. in the CN group [5.1 months [95% CI 3.6–6.8; HR 0.60; 95% CI 0.38–0.95; p = 0.005]). The rates of the key AEs (neutropenia and anaemia) were greater in the ACN group than in the CN group (all p < 0.05), but these AEs were manageable. CONCLUSION: Among selected populations of individuals with treatment-naïve, metastatic nonsquamous PD-L1-positive NSCLC, atezolizumab combined with carboplatin and nab-paclitaxel chemotherapy might have encouraging anticancer activity, with a tolerable safety profile. Springer Berlin Heidelberg 2022-01-01 2022 /pmc/articles/PMC9508031/ /pubmed/34973080 http://dx.doi.org/10.1007/s00432-021-03873-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article – Clinical Oncology Xu, Bo Cheng, Huihui Li, Kunhong Lv, Yukai Zeng, Xianshang Liu, Tao Yu, Weiguang Guo, Wenbo Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study |
title | Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study |
title_full | Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study |
title_fullStr | Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study |
title_full_unstemmed | Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study |
title_short | Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study |
title_sort | carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with pd-l1 staining: a retrospective study |
topic | Original Article – Clinical Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508031/ https://www.ncbi.nlm.nih.gov/pubmed/34973080 http://dx.doi.org/10.1007/s00432-021-03873-3 |
work_keys_str_mv | AT xubo carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy AT chenghuihui carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy AT likunhong carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy AT lvyukai carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy AT zengxianshang carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy AT liutao carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy AT yuweiguang carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy AT guowenbo carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy |